Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS Nephrology

Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis

View
Publications IgAN Nephrology

Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice

View
Publications FSGS

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative

View
Publications Nephrology

The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile

View
Medical Information IgAN

Measures of Proteinuria in IgA Nephropathy

Learn more
Publications FSGS

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

View
Publications Nephrology

Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease

View
Medical Information IgAN

FILSPARI (sparsentan): Patient-reported Outcomes in the Phase 3 PROTECT Study

Learn more
Medical Information FSGS

Sparsentan: Patient-reported Outcomes in the Phase 3 DUPLEX Study

Learn more
Publications IgAN

Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial

View
Publications FSGS

Sparsentan Improves Glomerular Hemodynamics, Cell Functions and Tissue Repair in a Mouse Model of FSGS

View
Publications IgAN

Sparsentan Ameliorates Glomerular Hypercellularity and Inflammatory-gene Networks Induced by IgA1-IgA Immune Complexes in a Mouse Model of IgA Nephropathy

View
Publications IgAN

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

View